With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13440-07-8,Di(naphthalen-1-yl)phosphine oxide,as a common compound, the synthetic route is as follows.
Example 3 Dinaphthylphosphine-borane complex Under an argon atmosphere, 4 mL of toluene was added to dinaphthylphosphine oxide synthesised in Reference Example 2 (0.6061 g, 2.00 mmol) at a room temperature (25C) and the mixture was stirred to obtain a suspension. Then, to the suspension was added 1.02 mol/L of a borane-tetrahydrofuran complex (5 mL, 2.55 equivalents). The reaction mixture was purified by silica gel column chromatography (silica gel 15 g, toluene) and the desired fraction was concentrated under reduced pressure. The residue was dried (under reduced pressure at 40C) to obtain the titled compound (0.4577 g, white powder). The yield was 76.2%. 1H-NMR (300 MHz, CDCl3, TMS) delta: 0.60-1.85 (m, 3 H), 6.56 (dq, 1 H, JH-P= 378.7 Hz, J = 6.9 Hz), 7.52-8.31 (m, 14H). 13C-NMR (75 MHz, CDCl3, CDCl3) delta: 124.40, 125.16, 128.53, 129.22, 129.31, 129.61, 129.96, 130.30, 130.43, 134.20, 134.36, 135.91, 135.94, 135.99, 136.14. 31P-NMR (121 MHz, CDCl3, 85% H3PO4) delta: 1.10-2.21 (m), 3.92-4.95 (m).
As the paragraph descriping shows that 13440-07-8 is playing an increasingly important role.
Reference£º
Patent; Takeda Pharmaceutical Company Limited; EP1626052; (2006); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate